Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6376593 | 0.87 | GABRA1 (0.53) | GABRA1GABRB2ALOX5ATMKDM4E | |
| SCHEMBL17527230 | 0.85 | ALOX5 (0.48) | GABRA1GABRB2ALOX5ATMKDM4E | |
| SCHEMBL31435284 | 0.85 | PTGS2 (0.48) | ATMKDM4EALDH1A1CYP19A1TSHR | |
| SCHEMBL11838721 | 0.83 | CA2 (0.61) | ATMKDM4EALDH1A1POLBTSHR | |
| SCHEMBL465047 | 0.82 | GABRA1 (0.49) | GABRA1GABRB2ALOX5ATMKDM4E | |
| SCHEMBL16638886 | 0.82 | KDM4E (0.53) | GABRA1GABRB2ALOX5ATMKDM4E | |
| SCHEMBL465122 | 0.82 | GABRA1 (0.46) | GABRA1GABRB2ALOX5ATMKDM4E | |
| SCHEMBL2563443 | 0.82 | GABRA1 (0.46) | GABRA1GABRB2ALOX5ATMKDM4E | |
| SCHEMBL27002044 | 0.81 | KDM4E (0.61) | ATMKDM4ECYP3A4TSHRMAPK1 | |
| SCHEMBL1829321 | 0.80 | NPC1 (0.47) | CYP3A4POLBTSHRMAPK1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200055817-A1 | SPIRO-COMPOUNDS AS SIP MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-02-20 | — | — | US | disclosed |
| US-20200055817-A1 | SPIRO-COMPOUNDS AS SIP MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-02-20 | — | — | US | disclosed |
| EP-3535244-A1 | SPIRO-COMPOUNDS AS S1P MODULATORS | Abbvie Deutschland GmbH & Co. KG (DE) | 2019-09-11 | — | — | EP | disclosed |
| US-10280159-B2 | Fused (hetero)cyclic compounds as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-05-07 | — | — | US | disclosed |
| EP-3394050-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017109095-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174672-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-06-22 | — | — | US | disclosed |
| EP-2354134-B1 | 2H-CHROMENE DERIVATIVES AS STIMULATORS OF SPHINGOSINE 1-PHOSPHATE RECEPTOR | ASTELLAS PHARMA INC (JP) | 2016-02-24 | — | — | EP | disclosed |
| EP-2371811-B1 | Azetidinecarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO (JP) | 2014-10-08 | — | — | EP | disclosed |
| US-20140023636-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-23 | — | — | US | disclosed |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| EP-1826197-B1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2012-01-18 | — | — | EP | disclosed |
| EP-2371811-A2 | Azetidinecarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-05 | — | — | EP | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2354134-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | Astellas Pharma Inc. (JP) | 2011-08-10 | — | — | EP | disclosed |
| US-20110105432-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-7906549-B2 | Aminocarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090275554-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1826197-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105432-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | EDNRA, EDNRB, S1PR1 | GABRA1 1147/4885GABRB2 2137/4885ALOX5 30/4885 |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, CCR1 | GABRA1 2160/4885GABRB2 3160/4885ALOX5 257/4885 |
| US-10280159-B2 | Fused (hetero)cyclic compounds as S1P modulators | S1PR1, S1PR2, S1PR3 | GABRA1 830/4885GABRB2 641/4885ALOX5 834/4885 |
| US-20140023636-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | EDNRA, EDNRB, S1PR1 | GABRA1 1147/4885GABRB2 2137/4885ALOX5 30/4885 |
| US-20090275554-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | EDNRA, EDNRB, S1PR1 | GABRA1 1147/4885GABRB2 2137/4885ALOX5 30/4885 |
| US-20170174672-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | S1PR1, S1PR2, S1PR3 | GABRA1 830/4885GABRB2 641/4885ALOX5 834/4885 |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, S1PR4 | GABRA1 1775/4885GABRB2 2315/4885ALOX5 377/4885 |
| US-20200055817-A1 | SPIRO-COMPOUNDS AS SIP MODULATORS | S1PR1, STIM1, GIPR | GABRA1 345/4885GABRB2 306/4885ALOX5 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.